# Forensic Dossier: Study Forensics: Rapamycin for human longevity — promise vs proof

**Run ID:** `mc2_study-forensics-031_claude_haiku_812edf`  
**Task:** study-forensics-031 | study_forensics | hard | study_forensics  
**Timestamp:** 2026-04-06T16:24:43.679008+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** strong_preclinical_weak_human  
**Ambiguity:** medium  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **73.4/100** (margin: 0.0)
**Failure modes:** named_not_explained, unsupported_conclusion, unused_assumption, wrong_answer
**Forensic flags:** 3
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 0.0/8 | 4.8/8 | 4.3/6 | 3.9/6 | 6.0/6 | 6.4/8 | 8.0/8 | 1.5/10 | 8.5/10 | **73.4/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `mechanism_vs_evidence` [+] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, decorative_uncertainty
**Extra Findings:** cautious_scope_control, none_or_minor, conclusion_exceeds_results, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "solid"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "solid"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "solid"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "solid"
    _Agent's answer for correctness check_
  - Note: No match (got: solid)

**Support Strength:** 0.0/8
  - (-) `final_answer`: "solid"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[1]`: "Checked for mechanism vs. evidence issues: The text does NOT claim the mouse mechanism (mTOR inhibition) directly transl"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.3/6
  - (+) `assumptions[2]`: "The trial's primary endpoint (abdominal fat reduction) and secondary endpoint (lean muscle) are appropriate proxies for "
    _Most substantive assumption_
  - (-) `assumptions[0]`: "The mouse lifespan extension data (10-25%) is accurately reported and represents genuine replication across labs"
    _Declared but unused in reasoning_
  - Note: 5/5 substantive assumptions
  - Note: 1 unused assumption(s)

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[2]`: "Whether the trial's endpoints (abdominal fat, lean muscle) were the most appropriate for detecting aging effects, or if "
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.88"
    _Stated confidence level_
  - Note: 4 uncertainties (4 substantive)
  - Note: Confidence 0.88

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[1]`: "Could argue the text should more explicitly state that abdominal fat and lean muscle are imperfect proxies for aging, bu"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 include rejection reasoning

**Self Monitoring Quality:** 6.4/8
  - (+) `self_check[5]`: "Did I assume the trial was well-designed without evidence? The text states this, and I accepted it as given; I flagged t"
    _Most substantive self-verification step_
  - Note: 6 self-check items
  - Note: Self-check quality: 0 deep, 6 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.69, 671 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'mechanism_vs_evidence'
  - `final_answer`: "solid"
  - _Impacts: correctness_

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "solid"
  - _Impacts: support_strength_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "solid"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_

**STYLISTIC:**
- **Unused Assumption** `[HEURISTIC]`: Assumption 'The mouse lifespan extension data (10-25%) is accurately rep...' is declared but not referenced in reasoning
  - `assumptions[0]`: "The mouse lifespan extension data (10-25%) is accurately reported and represents genuine replication"
  - _Impacts: assumption_discipline_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/11 content words)
  - `key_claims[0]`: "The text correctly distinguishes between animal evidence (robust) and human evidence (absent for agi"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/16 content words)
  - `key_claims[1]`: "The text appropriately notes that the human trial tested safety and specific body composition outcom"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/14 content words)
  - `key_claims[2]`: "The expert caution is evidence-based: it does not deny the mouse data or the trial's safety findings"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/13 content words)
  - `key_claims[3]`: "The text does not commit mechanism vs. evidence error: it does not claim mTOR inhibition in mice pro"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 5 has low overlap with final answer (0/8 content words)
  - `key_claims[4]`: "The risk warning is appropriately targeted (active cancer) rather than blanket"
- **[WARN]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Phenomenon is named but causal mechanism is not explained
  - `final_answer`: "solid"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 12118ms

**Final Answer:** solid

**Confidence:** 0.88

**Assumptions:**
- The mouse lifespan extension data (10-25%) is accurately reported and represents genuine replication across labs
- The human trial described is indeed 'well-designed' as stated
- The trial's primary endpoint (abdominal fat reduction) and secondary endpoint (lean muscle) are appropriate proxies for aging effects
- The text accurately represents expert consensus on current evidence
- Off-label use of rapamycin does carry the risks mentioned for the populations cited

**Reasoning Steps:**
1. Identified the core claim structure: mouse data → human enthusiasm → human trial results → expert caution
2. Checked for mechanism vs. evidence issues: The text does NOT claim the mouse mechanism (mTOR inhibition) directly translates to humans without evidence. It explicitly notes the human trial 'failed to reduce abdominal fat' and 'did not test whether the drug slows biological aging'
3. Checked for correlation vs. causation: The text does not make causal claims about rapamycin slowing aging in humans. It reports what the trial measured and what it did not measure
4. Checked for overclaim: The text explicitly states 'no clinical evidence yet shows rapamycin slows aging in people' — this is a clear, appropriately cautious statement that contradicts enthusiast claims
5. Checked for decorative uncertainty: The uncertainty here is substantive and well-integrated. The text distinguishes between mouse data (reliable), human safety (established), and aging effects in humans (not yet tested). This is not performative
6. Checked for confounders: The text does not make causal claims that would require confounder analysis. It reports trial outcomes and notes what was not tested
7. Evaluated the expert caution: The statement that 'no clinical evidence yet shows rapamycin slows aging in people' is appropriately evidence-based and the risk warning for specific populations (active cancer) is reasonable

**Key Claims:**
- The text correctly distinguishes between animal evidence (robust) and human evidence (absent for aging effects)
- The text appropriately notes that the human trial tested safety and specific body composition outcomes, but NOT biological aging — this is a crucial epistemic distinction
- The expert caution is evidence-based: it does not deny the mouse data or the trial's safety findings; it simply notes the absence of human aging data
- The text does not commit mechanism vs. evidence error: it does not claim mTOR inhibition in mice proves aging effects in humans
- The risk warning is appropriately targeted (active cancer) rather than blanket

**Alternative Hypotheses:**
- Could argue mild overclaim if 'reliably extends lifespan' in mice is overstated, but the text attributes this to replication across labs, which is defensible
- Could argue the text should more explicitly state that abdominal fat and lean muscle are imperfect proxies for aging, but the trial's failure to measure biological aging is already acknowledged

**Uncertainties:**
- Whether the mouse lifespan extension data truly represents robust replication or if some studies failed to replicate (the text claims replication but I cannot verify)
- The specific design quality of the human trial — the text calls it 'well-designed' but does not provide details on sample size, duration, or methodology
- Whether the trial's endpoints (abdominal fat, lean muscle) were the most appropriate for detecting aging effects, or if other biomarkers would have been more sensitive
- The magnitude of risk from off-label rapamycin use in non-cancer populations — the text mentions risks but does not quantify them

**Self-Verification:**
- Did I overread the text as making causal claims it does not make? No — the text carefully separates mouse lifespan data from human aging claims
- Did I miss an overclaim? The only potential overclaim is 'reliably extends lifespan' in mice, but this is attributed to replication, which is a reasonable standard
- Did I miss a mechanism vs. evidence problem? No — the text explicitly does not claim the mouse mechanism applies to humans without evidence
- Did I miss a correlation vs. causation problem? No — the text reports trial outcomes, not correlational associations
- Is the expert caution actually justified? Yes — the absence of human aging biomarker data in the trial is a genuine epistemic gap
- Did I assume the trial was well-designed without evidence? The text states this, and I accepted it as given; I flagged this as an uncertainty rather than assuming it was false

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.3/6 `#######...`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 6.4/8 `########..`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **73.4/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.3/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (6.4/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 12.1s | 73.4/100 | 6.1 |

Failure modes observed: named_not_explained, unsupported_conclusion, unused_assumption, wrong_answer.
